Argenx SE Reports Promising Phase 2 Results for Efgartigimod in Autoimmune Diseases

Argenx Se ( (ARGX) ) has issued an announcement.

On June 10, 2025, Argenx SE announced positive results from Phase 2 studies of their drug efgartigimod at the EULAR 2025 conference. The studies demonstrated significant improvements in patients with myositis and Sjogren’s disease, with efgartigimod showing potential as a precision therapy. The drug has also received Fast Track designation from the FDA for Sjogren’s disease, highlighting its potential impact on the treatment landscape for these autoimmune conditions.

The most recent analyst rating on (ARGX) stock is a Buy with a $514.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Spark’s Take on ARGX Stock

According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.

Argenx Se’s strong financial performance and positive earnings call are the most significant contributors to its overall score. However, technical indicators and valuation suggest caution, as the stock is trading below its long-term moving averages and appears overvalued compared to the market.

To see Spark’s full report on ARGX stock, click here.

More about Argenx Se

Argenx SE is a global immunology company focused on developing therapies for severe autoimmune diseases. The company is committed to advancing treatments in rheumatology, with ongoing studies targeting conditions such as myositis and Sjogren’s disease.

Average Trading Volume: 401,711

Technical Sentiment Signal: Buy

Current Market Cap: $35.39B

Learn more about ARGX stock on TipRanks’ Stock Analysis page.